Evotec SE (NASDAQ:EVO) Short Interest Up 104.3% in November

Evotec SE (NASDAQ:EVO) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 449,700 shares, a growth of 104.3% from the October 31st total of 220,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 195,200 shares, the short-interest ratio is currently 2.3 days.

Evotec Stock Down 2.9 %

NASDAQ:EVO traded down $0.14 during mid-day trading on Friday, hitting $4.69. 64,435 shares of the company’s stock traded hands, compared to its average volume of 134,065. The firm has a 50 day moving average of $3.95 and a two-hundred day moving average of $4.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. Evotec has a 12 month low of $2.85 and a 12 month high of $12.00.

Institutional Investors Weigh In On Evotec

Hedge funds have recently made changes to their positions in the stock. Vanguard Personalized Indexing Management LLC bought a new position in Evotec in the second quarter worth $87,000. Clear Harbor Asset Management LLC bought a new position in shares of Evotec during the 3rd quarter worth about $104,000. Cetera Advisors LLC acquired a new stake in shares of Evotec during the 1st quarter valued at about $188,000. Mediolanum International Funds Ltd bought a new stake in Evotec in the third quarter valued at about $512,000. Finally, DCF Advisers LLC lifted its stake in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares during the period. Institutional investors own 5.81% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group lowered shares of Evotec from a “buy” rating to a “hold” rating and decreased their target price for the company from $8.70 to $3.80 in a research note on Monday, October 7th. Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Evotec in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.93.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.